2022 Revenues ($USD) : $44,351,000,000.00
2022 R&D spend : $9,762,000,000.00
2022 Number of Employees : 83,500
Fiscal Year End : 12/31/22
Leader : CEO Pascal Soriot

The Cambridge, U.K.–headquartered global biopharmaceutical company reported strong financial performance in 2022, with total revenue reaching $44.4 billion, a 25% increase at constant exchange rates. Earnings per share for the year were $6.66, a 33% increase compared to the prior year. The company's diverse product portfolio and broad geographic footprint supported its growth. In 2022, AstraZeneca reported eight positive phase 3 readouts and 34 regulatory approvals in key markets. The company plans to initiate over 30 additional phase 3 studies in 2023, with 10 trials having blockbuster potential. AstraZeneca aims to launch at least 15 new medicines by the end of the decade, targeting industry-leading revenue growth in the long term. The company's 2023 guidance projects a high single-digit to low double-digit percentage increase in core EPS, anticipating a substantial decline in demand for COVID medicines. —BB